Drug intelligence / Profile preview

INSP003

Development stage: Preclinical
Lead developer: Ever Supreme Bio-Technology
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

INSP003 is a nanoparticle-based chemotherapy formulation of paclitaxel developed by Ever Supreme Bio Technology. It utilizes a nanoparticle delivery system to transport paclitaxel, a microtubule-stabilizing agent, to malignant tumors. By stabilizing microtubules and inhibiting their disassembly, paclitaxel interferes with mitotic spindle formation, leading to cell cycle arrest and apoptosis. This nanoparticle formulation is designed for broad anti-tumor activity across multiple tumor types (cross-tumor applications), potentially improving the solubility, pharmacokinetic profile, and therapeutic index of paclitaxel compared to conventional formulations.

Other names: INSP003 (nanoparticle-based chemotherapy)

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on INSP003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INSP003.

Explore the full profile